PP4 THE RELATIONSHIP BETWEEN ICS LABA ADMINISTRATION AND BLOOD EOSINOPHIL LEVELS IN COPD PATIENT AT USU GENERAL HOSPITAL

Olivia M. Deneuve, Andika Pradana, Amira P. Tarigan
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Sumatera Utara, Universitas Sematera Utara Hospital, Medan, Indonesia

Introduction:

Blood eosinophil are an important biomarker that varies substantialy over time in chronic obstructive pulmonary disease (COPD) patiens. A blood eosinophil count threshold ≥ 300 cells/μL identifies the association between eosinophils and ICS and can be used to identify patient with the greatest likelihood of benefit treatment with ICS.

Objectives:

To determine the relationship between ICS LABA and eosinophils level in COPD patient.

Methods:

This was a cohort retrospective study performed June-August 2022 to June-August 2023. Subjects were 44 COPD patients who treated at the USU General Hospital using ICS LABA therapy. Eosinophil levels were measured from blood samples. The Wilcoxon signed rank test was used to compare the eosinophil level.

Results:

The majority of research subject were male (77.3%), age >60 years old (75%) and CHF (31.8%) as the most comorbidities. The eosinophil level before admission ICS had a median value 40.89 (0.00-407.5) and eosinophil after admission ICS had a median value 0.00 (0.00-65.67). There was a relationship between ICS LABA administration and blood eosinophil level in COPD Patient (p-value = 0.002).

Conclusions:

Steroid medication use dramatically lowered blood levels of eosinophils, and the effects lasted longer than twenty-four hours for single-dose drug users. Numerous factors, including structural alterations in the respiratory airways, hypersecretion of mucus, and reduced recoil elasticity as a result of potential alveolar injury, affect how effective ICS LABA medications are.